

Title	Impurity occurrence and removal in crystalline products from process reactions
Author(s)	Moynihan, Humphrey A.; Horgan, Danielle E.
Publication date	2017-04-10
Original citation	Moynihan, H. A. and Horgan, D. E. (2017) 'Impurity occurrence and removal in crystalline products from process reactions', <i>Organic Process Research and Development</i> , 21(5), pp. 689-704. doi:10.1021/acs.oprd.6b00403
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://dx.doi.org/10.1021/acs.oprd.6b00403 Access to the full text of the published version may require a subscription.
Rights	© 2017, American Chemical Society. All rights reserved. This document is the Accepted Manuscript version of a Published Work that appeared in final form in <i>Organic Process Research and Development</i> , after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/acs.oprd.6b00403
Embargo information	Access to this article is restricted until 12 months after publication by request of the publisher.
Embargo lift date	2018-04-10
Item downloaded from	http://hdl.handle.net/10468/5006


Downloaded on 2019-01-19T23:25:04Z

Impurity Occurrence and Removal in Crystalline Products from Process Reactions

Humphrey A. Moynihan* and Danielle E. Horgan

SUPPLEMENTARY INFORMATION

Data on the incorporation into phenacetin 61 crystals of 4-phenetidine 63, acetanilide 120 and 4-methoxyacetanilide 121



Crystal growth Compounds and solvents were purchased from Sigma-Aldrich. Phenacetin (50 mg) and one of each impurity were mixed to give samples containing each impurity as either 5%, 10% or 15% of the total number of moles of each sample. These samples were dissolved in methanol (1.5 mL) with heating to 35 °C to ensure dissolution in all cases. The solutions were allowed to cool and partially (but not fully) evaporated in semi-covered (partially perforated) vials to allow growth of crystals of at least 0.5 × 0.5 × 0.2 mm dimensions. The crystals were isolated, washed with 0.4 mL of cold methanol, dried under vacuum and weighed.

Crystal dissolution For each impurity and concentration, individual crystals were subjected to a series of three partial dissolutions followed by analysis of the resulting solutions at each stage. The mass of the crystals determined the volumes of solvent used for complete dissolution, to give a concentration of 1.0 mg/mL, e.g. 6.0 mL was used for the complete dissolution of a crystal weighing 6.0 mg, with 2.0 mL used for each of the three partial dissolution stages. At the beginning of the series of dissolutions, the crystal was placed in a sample vial. The correct volume of solvent was added and the crystal was observed partially dissolving. It was then removed and washed with a small quantity of cold hexane before being placed in a second sample vial to be further dissolved. This process was repeated for a third final stage giving complete dissolution. The solutions remaining in the sample vials were analysed by HPLC. Each of these experiments was repeated three times.

HPLC HPLC analysis on the products was conducted on an Agilent 1200 series HPLC, with a YMC-Pack ODSA column (250 x 4.6 mm, 5 μ m). An isocratic 60:40 MeOH:H₂O solvent system was employed, at a flow rate of 1 mL/min and an injection volume of 10 μ L. The detector was set at 254 nm and the oven temperature was ambient.

Table S1 Relative quantities (percentage area by HPLC) of impurity compounds **63**, **120** and **121** incorporated into crystals of phenacetin **61** determined at three successive dissolution stages.

Impurity	Mol % impurity in solution	% impurity in 1 st dissolution layer	% impurity in 2 nd dissolution layer	% impurity in 3 rd dissolution layer
63	5, 10 or 15	<LOQ ^a	<LOQ ^a	<LOQ ^a
120	5	1.61 \pm 0.01	0.31 \pm 0.04	0.20 \pm 0.01
120	10	2.28 \pm 0.02	0.56 \pm 0.02	0.45 \pm 0.01
120	15	5.89 \pm 0.03	1.44 \pm 0.02	0.49 \pm 0.03
121	5	2.88 \pm 0.02	2.58 \pm 0.01	2.53 \pm 0.02
121	10	6.11 \pm 0.01	5.23 \pm 0.02	4.97 \pm 0.01
121	15	7.64 \pm 0.02	7.36 \pm 0.04	6.52 \pm 0.03

^a 3.5 x 10⁻³ mg/mL